 |
 Video: What is a Stock Split?
|
|
|
| Kinnate is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for genomically defined cancers. Co.'s focus is on three patient populations: those with cancers that harbor known oncogenic drivers with no available targeted therapies; those with genomically well-characterized tumors that have resistance to available treatments; and those whose tumors have acquired resistance over the course of therapy to available treatments. Co.'s product candidates are KIN002787, which is for the treatment of patients with lung cancer, melanoma and other solid tumors; and KIN-3248, which is targeting cancer-associated alterations in FGFR2. According to our Kinnate Biopharma stock split history records, Kinnate Biopharma has had 0 splits. | |
|
Kinnate Biopharma (KNTE) has 0 splits in our Kinnate Biopharma stock split history database.
Looking at the Kinnate Biopharma stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Kinnate Biopharma shares, starting with a $10,000 purchase of KNTE, presented on a split-history-adjusted basis factoring in the complete Kinnate Biopharma stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
12/04/2020 |
|
| End date: |
04/03/2024 |
|
| Start price/share: |
$43.46 |
|
| End price/share: |
$2.65 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-93.90% |
|
| Average Annual Total Return: |
-56.84% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$609.92 |
|
| Years: |
3.33 |
|
|
|
|
|
